BioSig Technologies Sponsors The 11th International Symposium on Ventricular Arrhythmias

Minneapolis, MN, Sept. 26, 2016 (GLOBE NEWSWIRE) — BioSig Technologies (OTCQB:BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, today announced they have provided an unrestricted educational grant to The 11th International Symposium on Ventricular Arrhythmias: Pathophysiology & Therapy hosted by The Mount Sinai Hospital in New York and the University of Pennsylvania Health System in Philadelphia to be held at the New York Hilton Midtown on October 7 and 8, 2016. The course has been developed to meet the educational needs of electrophysiologists and other physicians with an interest in the pathophysiology and management of ventricular arrhythmias.
The purpose of the Annual International Symposium on Ventricular Arrhythmias is to provide a current review of new information on the basic pathophysiology of ventricular arrhythmias and to provide an in-depth understanding of the current management strategies used for the management of ventricular arrhythmias in various disease states.
Greg Cash, President and Chief Executive of BioSig Technologies, said, “Providing support for this important symposium underscores BioSig’s commitment to helping to improve outcomes in patients with complex arrhythmias, in this case ventricular tachycardias and ventricular fibrillation, which result in over 450,000 sudden cardiac deaths per year in the United States alone.”
Jay Millerhagen, BioSig’s VP of Clinical Research plans to attend the symposium and will be available to meet those interested in reviewing the Company’s pre-clinical work to date. To set up a meeting, please emailjmillerhagen@biosigtech.com.
Connect with BioSig Technologies (OTCQB:BSGM) to receive an Investor Presentation.